
Sign up to save your podcasts
Or


Carlos Fernández de Larrea (Hospital Clínic de Barcelona, Barcelona, Spain) and Damian Green (Fred Hutch Cancer Center, Seattle, WA, USA) discuss their studies on BCMA CAR T cells in patients with relapsed or refractory multiple myeloma.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00246-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
By The Lancet Group5
11 ratings
Carlos Fernández de Larrea (Hospital Clínic de Barcelona, Barcelona, Spain) and Damian Green (Fred Hutch Cancer Center, Seattle, WA, USA) discuss their studies on BCMA CAR T cells in patients with relapsed or refractory multiple myeloma.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00246-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

7,589 Listeners

137 Listeners

320 Listeners

497 Listeners

40 Listeners

17 Listeners

11 Listeners

57 Listeners

11 Listeners

44 Listeners

32 Listeners

93 Listeners

21 Listeners

0 Listeners

0 Listeners

2 Listeners

0 Listeners

2 Listeners

1 Listeners

0 Listeners

0 Listeners

1 Listeners

1 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

115 Listeners

192 Listeners

44 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners